On December 19, 2019, the shipment of the NEW antihypertensive drug NEBIVOLO-NAN, manufactured by the State Enterprise “ACADEMPHARM”, began. Nebivolol-NAN is a highly selective third-generation Beta1-adrenergic blocker that provides an additional vasodilator effect by modulating the release of an endothelium-dependent relaxing factor for the treatment of arterial hypertension and heart failure.
INN: Nebivolol
Dosage and packing: 5 mg No. 30
The main characteristics of the new drug:
- Improves the quality of life of patients with hypertension
- Well tolerated
- Does not reduce physical performance
- Does not affect sexual performance
Interesting in the press center
Neurology conference 10.12.2019
Presentation on the topic “Prospects for the use of dietary supplements CURCUMIN in sports”
Potential of RANOLAZINE in improving the quality of life of patients with coronary heart disease. – Download the article
Day of Belarusian Science 2020